Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • Learning Objectives After completing this course, the reader will be able to: Describe the benefits of bisphosphonate treatment in patients with bone metastases from breast cancer.Summarize the association between decreases in elevated urinary NTX levels during the first 3 months of zoledronic acid treatment and clinical outcomes such as survival, time to disease progression, and time to first SRE.Describe the association, if any, between bone marker levels and an impending SRE. Access and take the CME test online and receive 1 AMA PRA Category 1 Creditâ„¢ at CME.TheOncologist.com

authors

  • Lipton, Allan
  • Cook, Richard J
  • Major, Pierre
  • Smith, Matthew R
  • Coleman, Robert E

publication date

  • September 1, 2007